JMP Securities Reaffirms Market Outperform Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “market outperform” rating reissued by stock analysts at JMP Securities in a research note issued on Tuesday,Benzinga reports. They presently have a $4.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $7.00. JMP Securities’ price target indicates a potential upside of 127.92% from the company’s current price.

Several other equities analysts have also commented on ESPR. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR traded down $0.11 during mid-day trading on Tuesday, hitting $1.76. The company had a trading volume of 1,411,687 shares, compared to its average volume of 4,580,047. The stock has a market cap of $345.81 million, a price-to-earnings ratio of -2.71 and a beta of 1.01. The firm’s 50 day simple moving average is $2.33 and its two-hundred day simple moving average is $2.13. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Large investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company acquired a new position in Esperion Therapeutics in the 2nd quarter valued at approximately $159,000. SG Americas Securities LLC increased its stake in shares of Esperion Therapeutics by 105.9% during the 3rd quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 39,635 shares during the last quarter. Boomfish Wealth Group LLC raised its holdings in shares of Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 5,102 shares in the last quarter. Traphagen Investment Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the 3rd quarter valued at $27,000. Finally, Versor Investments LP bought a new stake in Esperion Therapeutics in the third quarter worth $44,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.